08.16.2017
Prevent & Delay
$33,674,060.00
96 months
The GPPAD-03 Study: The Primary Oral Insulin Trial
Funding Helmholtz Zentrum München to support a multisite, European primary prevention clinical trial for type 1 diabetes.